Lionsgate Studios Corp. filings document the regulatory record of a British Columbia entertainment company with NYSE-listed common shares and rights to purchase common shares. Its 8-K reports cover operating results, material agreements, credit facilities secured by intellectual property rights associated with library titles, board appointments, shareholder meetings and executive compensation arrangements.
Proxy and meeting-related filings describe director elections, auditor ratification, advisory votes on executive pay, shareholder proposal procedures and governance matters. The filing record also includes disclosures on capital structure, registered securities, standstill and voting agreements, and formal results of shareholder votes.
Lionsgate Studios Corp. (LION) reported that director Harry Sloan acquired common shares on September 15, 2026 through equity compensation. He received 13,405 common shares at no cost as an annual director equity award and 5,362 common shares at $11.19 per share as director fees paid in common shares. A related footnote states that his holdings include 33,512 restricted share units, scheduled to vest in tranches on November 28, 2026 and September 15, 2027, each payable in an equal number of common shares. No Rule 10b5-1 trading plan is reported for these awards.
Lionsgate Studios Corp. (LION) director M. Richard Rosenblatt reported two equity-related acquisitions of common shares on September 15, 2026. He received 13,405 shares as an annual director equity award at a stated price of $0 per share, and 4,468 shares as director fees paid in common shares at $11.19 per share. Footnotes state his holdings include 20,107 restricted share units scheduled to vest on November 28, 2026 and 13,405 restricted share units scheduled to vest on September 15, 2027, each payable in an equal number of common shares upon vesting. No Rule 10b5-1 trading plan is indicated.
Lionsgate Studios Corp. (LION) director Yvette Ostolaza reported two equity-related acquisitions of common shares on September 15, 2026. She received 13,405 common shares at $0.00 per share as an annual director equity award, structured as restricted share units that are scheduled to vest on September 15, 2027. She also acquired 5,362 common shares at $11.19 per share as director fees paid in common shares, with all such awards and units held directly and no Rule 10b5-1 trading plan reported.
Lionsgate Studios Corp. (LION) reported that director Susan McCaw received an annual director equity award of 13,405 common shares on September 15, 2026, recorded as a grant or award acquisition at no cash price. Following this grant, she holds 114,431 common shares directly, including restricted share units scheduled to vest on November 28, 2026 and September 15, 2027. No Rule 10b5-1 trading plan is reported for this transaction.
Lionsgate Studios Corp. (symbol: LION) is the issuer of record for a Form 4 filing submitted to the SEC. HARKEY JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. (LION) reports that director John D. Harkey Jr. received equity compensation on September 15, 2026. He was granted 13,405 Common Shares at no cost as an annual director equity award and 5,809 Common Shares as director fees valued at $11.19 per share, both held directly. The company also notes he holds restricted share units covering 20,107 shares scheduled to vest on November 28, 2026 and 13,405 shares scheduled to vest on September 15, 2027, each payable in an equal number of common shares. No Rule 10b5-1 trading plan is indicated.
Lionsgate Studios Corp. (symbol: LION) is the issuer of record for a Form 4 filing submitted to the SEC. Crawford Gordon reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. director Crawford Gordon reported two stock-based compensation grants of common shares on September 15, 2026. He received 13,405 common shares as an annual director equity award at no cash cost, and 4,468 common shares as director fees paid in shares at $11.19 per share. Footnotes state that his equity holdings also include 20,107 restricted share units scheduled to vest on November 28, 2026 and 13,405 restricted share units scheduled to vest on September 15, 2027, each payable in an equal number of common shares upon vesting.
Lionsgate Studios Corp. (symbol: LION) is the issuer of record for a Form 4 filing submitted to the SEC. RACHESKY MARK H MD reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. (LION) director and ten percent owner Mark H. Rachesky, M.D. reported equity compensation awards in the form of Common Shares and restricted share units. On September 15, 2026, he received 6,792 Common Shares as director fees and 13,405 restricted share units priced at $11.19 per share, with the RSUs payable in an equal number of Common Shares upon vesting. One RSU grant is scheduled to vest in a single installment on September 15, 2027, and another previously granted RSU award is scheduled to vest on November 28, 2026. The filing also describes substantial indirect holdings of Lionsgate Common Shares through multiple MHR-managed investment entities, for which Dr. Rachesky and related entities may be deemed to beneficially own shares but disclaim beneficial ownership except to the extent of their pecuniary interest.
Lionsgate Studios Corp. (symbol: LION) is the issuer of record for a Form 4 filing submitted to the SEC. FINE EMILY reported acquisition or exercise transactions in this Form 4 filing.
Lionsgate Studios Corp. (LION) reported that director Emily Fine received equity-based compensation on September 15, 2026. She was granted 4,468 Common Shares as director fees and 13,405 restricted share units, each RSU payable in one Common Share upon vesting on September 15, 2027.
A separate holding entry notes additional restricted share units previously granted that are scheduled to vest in one installment on November 28, 2026. No Rule 10b5-1 trading plan is reported for these equity awards.
Lionsgate Studios Corp. (LION) reported the results of its September 15, 2026 Annual General and Special Meeting of Shareholders, where 91.47% of common shares entitled to vote were represented. Shareholders elected all nominated directors, each receiving between 81.06% and 99.57% of votes cast in favor.
Shareholders also approved the reappointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 98.24% of votes cast in favor. An advisory vote on executive compensation passed with 83.22% support, and shareholders favored holding this advisory vote every year, with 94.61% of votes cast supporting a one-year frequency.
Lionsgate Studios Corp. reported results for the quarter ended June 30, 2026. Revenues were $776.6 million, compared with $525.9 million a year earlier, producing operating income of $25.6 million versus an operating loss of $10.6 million. Net loss from continuing operations was $29.3 million, and net loss attributable to shareholders was $28.8 million, or $0.10 per basic and diluted share.
As of June 30, 2026, cash, cash equivalents and restricted cash totaled $499.4 million, with total corporate debt of $1,938.9 million and film related obligations of $2,045.3 million, contributing to a shareholders’ equity deficit of $1,200.2 million. Motion Picture segment revenue was $587.3 million and Television Production revenue was $189.3 million, generating total segment profit of $115.2 million. Net cash provided by operating activities from continuing operations was $54.1 million.